Victory Capital Management Inc. Trims Stake in SI-BONE, Inc. (NASDAQ:SIBN)

Victory Capital Management Inc. trimmed its holdings in SI-BONE, Inc. (NASDAQ:SIBN - Free Report) by 11.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 407,378 shares of the company's stock after selling 52,960 shares during the period. Victory Capital Management Inc. owned about 0.97% of SI-BONE worth $5,711,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. FMR LLC lifted its position in shares of SI-BONE by 103.6% in the third quarter. FMR LLC now owns 2,354 shares of the company's stock valued at $33,000 after acquiring an additional 1,198 shares in the last quarter. Mainstream Capital Management LLC purchased a new position in shares of SI-BONE in the fourth quarter valued at about $53,000. R Squared Ltd purchased a new position in shares of SI-BONE in the fourth quarter valued at about $73,000. Walleye Capital LLC purchased a new position in shares of SI-BONE in the third quarter valued at about $144,000. Finally, Proficio Capital Partners LLC purchased a new position in shares of SI-BONE in the fourth quarter valued at about $155,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SI-BONE Price Performance

SI-BONE stock traded up $0.04 during midday trading on Friday, reaching $14.75. 183,199 shares of the stock traded hands, compared to its average volume of 352,960. The stock's fifty day moving average is $16.54 and its 200-day moving average is $14.86. SI-BONE, Inc. has a 12 month low of $11.70 and a 12 month high of $19.16. The stock has a market cap of $626.18 million, a P/E ratio of -16.03 and a beta of 1.17. The company has a quick ratio of 7.22, a current ratio of 8.25 and a debt-to-equity ratio of 0.22.

Remove Ads

SI-BONE (NASDAQ:SIBN - Get Free Report) last issued its quarterly earnings data on Monday, February 24th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.05. SI-BONE had a negative return on equity of 22.51% and a negative net margin of 23.82%. The business had revenue of $49.00 million for the quarter, compared to the consensus estimate of $48.87 million. As a group, equities research analysts anticipate that SI-BONE, Inc. will post -0.78 EPS for the current year.

Insider Buying and Selling at SI-BONE

In other news, CFO Anshul Maheshwari sold 5,304 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now directly owns 189,319 shares in the company, valued at approximately $2,633,427.29. This represents a 2.73 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Anthony J. Recupero sold 3,670 shares of the stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $13.90, for a total value of $51,013.00. Following the completion of the sale, the insider now owns 222,814 shares in the company, valued at approximately $3,097,114.60. The trade was a 1.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 9,311 shares of company stock worth $130,356 over the last ninety days. Company insiders own 3.90% of the company's stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Truist Financial restated a "buy" rating and issued a $22.00 price objective (up from $18.00) on shares of SI-BONE in a research report on Tuesday, February 25th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 target price on shares of SI-BONE in a research report on Tuesday, February 25th. Finally, Needham & Company LLC increased their price target on SI-BONE from $20.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, February 25th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $24.50.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.